60 Degrees Pharmaceuticals Inc (SXTP) Quote

SXTP.............................................https://stockcharts.com/h-sc/ui?s=SXTP&p=W&b=5&g=0&id=p86431144783

60 Degrees Pharmaceuticals Announces Third Quarter 2024 Results
11/14/2024 02:31:00 PM

sxtp..............................https://stockcharts.com/h-sc/ui?s=sxtp&p=W&b=5&g=0&id=p86431144783

SXTP......................................https://stockcharts.com/h-sc/ui?s=SXTP&p=W&b=5&g=0&id=p86431144783

Smells good 

SXTP..................................https://stockcharts.com/h-sc/ui?s=SXTP&p=W&b=5&g=0&id=p86431144783

Turnaround?!

SXTP new 52 week low

missed the bottom or a bottom at .91 cant believe how much this has fallen. Turns out my lifetime cost is actually higher than I thought even with some decent trading, so I am disappointed with this trade to date. Nonetheless I believe in what they are pursuing and expecting a rebound at any time where I will take profits probably above 1.45

currently I am trying to buy back shares I had sold at higher prices, down here if you sell at say 1.90 and buy back at 1.30, youre doing good due to the % difference and leverage at the lower prices. I feel like the current price, after all this stock has gone thru, including the dilution, is decent, but on any spikes to 2 bucks I would do some selling and continue doing so at higher prices. Sometimes you are stuck in some of these for a while, you dont control the timing, the market does, but if you are patient enough, and its a good company, you're spike should eventually come.

Looks like an offering is going to drop at a $1

SXTP...............................https://stockcharts.com/h-sc/ui?s=SXTP&p=W&b=5&g=0&id=p86431144783

SXTP.............................https://stockcharts.com/h-sc/ui?s=SXTP&p=W&b=5&g=0&id=p86431144783

Every time I see a ad on cnbc. The stock is done 4 life

RS was the nail in the coffin!

cost to borrow touch 467%, and 87, currently let's see how it plays into the rest of the week float still super low

I just bought in here at $1.64 any day ihub crew owning this?

https://www.zacks.com/stock/news/2300964/the-zacks-analyst-blog-highlights-danaher-morgan-stanley-pfizer-elite-pharmaceuticals-and-oil-dri

https://www.zacks.com/stock/news/2300922/zacks-initiates-coverage-of-elite-pharmaceuticals-with-outperform-recommendation

https://x.com/NuntioBot/status/1816458982258598229

https://dilutiontracker.com/app/search/SXTP?a=dbb88c

No comment

I almost refueled my entire position, that is absolutely breathtaking what happened today. Which is exactly why I said taking profits is paramount, the news while important is trumped by price. I still believe in what theyre doing or I wouldnt have bought back. Now the fun "can" begin again, if it rallies say to .30s I would start my selling again. Rinse and repeat. Dont marry the stock, marry the price.

SXTP...................................https://stockcharts.com/h-sc/ui?s=SXTP&p=W&b=5&g=0&id=p86431144783

you wouldnt be saying that if you had a relative who had this tickborn infection, or if you have ever had one yourself like I have. This is not garbagio this is a serious stab at solving a huge issue.

DUMPO GARBAGGIO !!!

AH & NW should be fun

well take a look its pulled back to the .35s, if you believe strongly you should be buying strongly right here. I am also buying and will buy in increasing volume if it keeps dropping.

Anythings possible in the NSDQ

Alot of diamond hands

even if you believe that, its better to let it pull back especially down here in this range where your leverage is huge if you think its going much higher, you buy a lot more shares at .32 than .42 or even .29 or below, dont fool yourself it can go there.

Cmon slap that ask $$$$$

$10 minimum

maybe but nobody knows.my highest sale at .585 almost cleaned me out of shares, just started buying back at .405, and I will keep buying in larger volume IF it drops. But I am not marrying any stocks especially biotechs no friggin way.

It's going to 10 plus

absolutely breathtaking, I sold a lot of shares too low price but thats ok, if this hits 60 cents today I'll be completely out, and I will not complain one iota, nobody can predict how high these things can go but they surely can pull back in a huge way as well. Take profits, it never hurts to take profits.

$SXTP
https://x.com/autumnsdad1/status/1814272797801144387?s=61

really missed out on some profits on the spike the other day in the pre-market since I cant trade till 7am and the news was out at 6:30 and it hit close to 40 cents. I would have taken some profits but probably not enough so its making me think it through a bit for the next opportunity how I will respond.

SXTP....................................https://stockcharts.com/h-sc/ui?s=SXTP&p=W&b=5&g=0&id=p86431144783

60 Degrees Pharma Announces IRB Approval of Clinical Study of Tafenoquine for Treatment of Babesiosis in Immunocompromised Patients with Persistent Babesia microti Despite Prior Treatment

Presumably this : https://clinicaltrials.gov/study/NCT06478641?cond=Babesiosis&rank=2

is to confirm the Yale study of the use of Tafenoquine for babesiosis: https://ysph.yale.edu/news-article/antimalarial-drug-is-effective-against-tick-borne-infection-babesiosis/

Last time there was a similar announcement it took off from 90 cents to 1.53 high) on 23 mill shares:

https://investors.60degreespharma.com/news-releases/news-release-details/60-degrees-pharma-announces-irb-approval-phase-iia-study

https://www.biospace.com/article/releases/first-patient-enrolled-in-60-degrees-pharmaceuticals-clinical-trial-of-tafenoquine-for-babesiosis-at-tufts-medical-center-first-and-only-study-of-its-kind/

continued buying down to .21, then took some profit up towards .40 and buying back on the pullback since then, but didnt trade as well as I would have liked, leaving me now with about 40K with lifetime cost around .24, not bad, but I really want to see this take off. At this point would do some selling in the mid-30s. This could be a real winner

Five immuno compromised patients cured of Babesioses given off label by doctors -this is getting interesting

40% of Lyme disease patients have Babesia https://danielcameronmd.com/babesia-and-lyme-its-worse-than-you-think/

Recruitment of at least 24 hospitalized patients diagnosed with babesiosis will begin after a site initiation visit at Tufts Medical Center on June 13, 2024.

Babesiosis is a steadily emerging, infectious disease transmitted by a microscopic parasite, Babesia, through the bite of the black-legged (deer) tick, the vector that spreads Lyme disease. Babesiosis, an orphan disease, may be life-threatening in elderly and immunosuppressed patients. Up to 10 percent of Lyme disease patients may be coinfected with Babesia. Therefore, up to 47,600 of the estimated 476,000 patients with new Lyme infections each year may be coinfected with Babesia.

“With tick-borne illnesses on the rise in the U.S., babesiosis is rapidly emerging as a condition of serious clinical concern,” said Dr. Geoff Dow, chief executive officer at 60 Degrees Pharmaceuticals. “The literature suggests tafenoquine may be a promising alternative for the treatment of patients hospitalized with relapsing babesiosis, so we are pleased to partner with Tufts Medical Center to conduct the first clinical trial of tafenoquine in treating hospitalized babesiosis patients. The results may eventually lead to an expanded indication for tafenoquine that will address this growing public health concern.”

Tufts Medical Center is one of several prominent university hospitals planning to participate in the study. 60 Degrees Pharmaceuticals is in negotiations with other leading university hospitals in the Northeast U.S. to add two other clinical trial sites.

Tafenoquine is approved for malaria prophylaxis in the United States under the product name ARAKODA®. The safety of the approved regimen of tafenoquine for malaria prophylaxis has been assessed in five separate randomized, double-blind, active comparator or placebo-controlled trials for durations of up to six months. Tafenoquine has not been proven to be effective for treatment or prevention of babesiosis and is not approved by the U.S. Food and Drug Administration for such an indication.

About the Study of Tafenoquine for Patients Hospitalized with Babesiosis

The study is a randomized, double-blind, placebo-controlled trial that will enroll patients at multiple sites in the Northeast U.S. and will compare the safety and efficacy of tafenoquine versus placebo in patients hospitalized for babesiosis. The two main study endpoints will be the time to sustained clinical resolution of symptoms and the time to molecular cure as determined by an FDA-approved nucleic acid test (NAT). At least 24, and as many as 33 patients, will be recruited before an interim analysis is conducted. Sufficient enrollment capacity is planned to allow all study subjects to be recruited during the 2024 tick season (June to September) if caseload is high. The interim analysis will include both a test of significance, as well as size re-estimation to allow additional recruitment if required. The study will be conducted at three hospitals in the Northeast U.S. The efficacy and safety of 8-aminoquinolines, a class of drugs that includes tafenoquine and primaquine, for prevention and treatment of malaria is well documented. Several case reports of tafenoquine use for babesiosis indicate that the drug is already being used for this purpose in the practice of medicine in the U.S.

About ARAKODA® (tafenoquine)
Tafenoquine was discovered by Walter Reed Army Institute of Research. Tafenoquine was approved for malaria prophylaxis in 2018 in the United States as ARAKODA® and in Australia as KODATEF®. Both were commercially launched in 2019 and are currently distributed through pharmaceutical wholesaler networks in each respective country. They are available at retail pharmacies as a prescription-only malaria prevention drug. According to the Centers for Disease Control and Prevention, the long terminal half-life of tafenoquine, which is approximately 16 days, may offer potential advantages in less-frequent dosing for prophylaxis for malaria. ARAKODA is not suitable for everyone, and patients and prescribers should review the Important Safety Information below. Individuals at risk of contracting malaria are prescribed ARAKODA 2 x 100 mg tablets once per day for three days (the loading phase) prior to travel to an area of the world where malaria is endemic, 2 x 100 mg tablets weekly for up to six months during travel, then 2 x 100 mg in the week following travel.

ARAKODA® (tafenoquine) Important Safety Information
ARAKODA® is an antimalarial indicated for the prophylaxis of malaria in patients aged 18 years of age and older.

Contraindications
ARAKODA® should not be administered to:

Glucose-6-phosphate dehydrogenase (“G6PD”) deficiency or unknown G6PD status;
Breastfeeding by a lactating woman when the infant is found to be G6PD deficient or if
G6PD status is unknown;
Patients with a history of psychotic disorders or current psychotic symptoms; or
Known hypersensitivity reactions to tafenoquine, other 8-aminoquinolines, or any component of ARAKODA®.
Warnings and Precautions
Hemolytic Anemia: G6PD testing must be performed before prescribing ARAKODA® due to the risk of hemolytic anemia. Monitor patients for signs or symptoms of hemolysis.
G6PD Deficiency in Pregnancy or Lactation: ARAKODA® may cause fetal harm when administered to a pregnant woman with a G6PD-deficient fetus. ARAKODA® is not recommended during pregnancy. A G6PD-deficient infant may be at risk for hemolytic anemia from exposure to ARAKODA® through breast milk. Check infant’s G6PD status before breastfeeding begins.
Methemoglobinemia: Asymptomatic elevations in blood methemoglobin have been observed. Initiate appropriate therapy if signs or symptoms of methemoglobinemia occur.
Psychiatric Effects: Serious psychotic adverse reactions have been observed in patients with a history of psychosis or schizophrenia, at doses different from the approved dose. If psychotic symptoms (hallucinations, delusions, or grossly disorganized thinking or behavior) occur, consider discontinuation of ARAKODA® therapy and evaluation by a mental health professional as soon as possible.
Hypersensitivity Reactions: Serious hypersensitivity reactions have been observed with administration of ARAKODA®. If hypersensitivity reactions occur, institute appropriate therapy.
Delayed Adverse Reactions: Due to the long half-life of ARAKODA® (approximately 17 days), psychiatric effects, hemolytic anemia, methemoglobinemia, and hypersensitivity reactions may be delayed in onset and/or duration.
Adverse Reactions: The most common adverse reactions (incidence greater than or equal to 1 percent) were: headache, dizziness, back pain, diarrhea, nausea, vomiting, increased alanine aminotransferase (ALT), motion sickness, insomnia, depression, abnormal dreams, and anxiety.
Drug Interactions
Avoid co-administration with drugs that are substrates of organic cation transporter-2 (OCT2) or multidrug and toxin extrusion (MATE) transporters.

Use in Specific Populations
Lactation: Advise women not to breastfeed a G6PD-deficient infant or infant with unknown G6PD status during treatment and for 3 months after the last dose of ARAKODA®.
To report SUSPECTED ADVERSE REACTIONS, contact 60 Degrees Pharmaceuticals, Inc. at 1- 888-834-0225 or the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. The full prescribing information of ARAKODA® is located here.

About 60 Degrees Pharmaceuticals, Inc.

https://stockcharts.com/h-sc/ui?s=SXTP&p=D&yr=0&mn=5&dy=10&id=p24986097784&listNum=23&a=1113701411

https://stockcharts.com/h-sc/ui?s=sxtp&p=W&yr=1&mn=6&dy=0&id=p24986097784&listNum=23&a=1113701411

need .29 break

https://stockcharts.com/h-sc/ui?s=SXTP&p=D&yr=0&mn=5&dy=10&id=p24986097784&listNum=23&a=1113701411

wants eod push

goal is to see 1 here and buy .AZTR before the run